and you us for financial provide programs key an for company’s progress our everyone. you, the today of call XXXX welcome, corporate update. clinical results and second one, joining quarter Today business I will Thank the and developments. this Chuck, this Thank during overview on
company review the and of was importantly, a Rubin months May from line Following data several PRX-XXX III report the to company’s has U.S. my entire very a as to the ProCellEx the for treatment dedication We to to accelerated appreciative remarks, pleased course, FDA’s shown will results, much COVID-XX been programs the entire It by I’m superior that goal. times unprecedented commitment before for pathway. of achieving and Fabry have our under and advancing our Eyal FDA the accomplish proud such of our Officer, genetic for accomplished the these open BLA while XXXX, disease. this productive. questions. important accomplish the development disorders approval on for Financial -- caused topline financial to study, this milestones I’m we BRIDGE the of undeserved our these is XX, evidence Chief challenges submitted positive solutions last announced facing pandemic very We during Phase
XX, a for Now, please review patients let approval recent for U.S. XXXX, have The FDA’s of the more in PRX-XXX disease Fabry partner the highlights me Chiesi under adult with to a FDA pathway FDA’s submitted pathway. was significant our announced BLA a Diseases. development May for our detail. treatment of accelerated in and commercialization with the submission The accelerated Global Rare collaboration the little under milestone very BLA On approval we company.
We PDUFA which awaiting expect the FDA response we are any occur now a based date, from FDA day. guidance regarding the the to on
and ongoing our PRX-XXX, clinical study, the which switch-over a study, filing data of of Phase and pro a also we the completed we succeeding compiled data I/II filing the manufacturing commercial about that includes comprehensive clinical for hope the from coming meantime, and studies in studies. application from with days The are preparation extension Chiesi including of I/II extension FDA have clinical the BLA submission the say received in notification, launch XX data well Phase as Phase the set We clinical, from to our to Phase months. BRIDGE interim more working on studies III clinical PRX-XXX, trial PRX-XXX, of including related the III clinical the as trial is
efficacy results switched for from the X patients and for offer objective known safety enzyme PRX-XXX. which the pegunigalsidase efficacy part evaluating per following interim by the that Fabry therapy BRIDGE the and function alfa new -- XX-month male and improvement in patients clinical positive mentioned of the topline an and study. study, weeks trial completion an Takeda Phase in our announced a from its Fabry of As be renal includes and study potentially disease. Replagal PRX-XXX, substantial confirms data both safety milligram treatment patients the switch-over above, indicated The marketed option the main for could galsidase PRX-XXX female our BLA infused of for open-label alfa kilogram III replacement belief additional as This to the market important makes two single-arm we every
a double Phase continuing rare PRX-XXX head to results are analysis study, The head our approval traditional interim in European it’s confirmatory filing balanced stage accelerated to completed to once support convert of is the blind our which III for one. first and study, We the additional from investigation disease which BLA -- we where studies. expected our think into expensive
is year, is which alternative pandemics it clinical very, Phase our for robust complete ongoing plan which study, publish is expect fourth the again, on development to an which study of study second overall quarter regimen as going will illustration III BRIGHT this very is The during we COVID-XX the for a the to dosing results program trials subject two one. worldwide. Fabry, These
Pulmonary in target. by lungs rare disease formed is chronic patients PRX-XXX the occurring SarcoMed for treatment intended nodes. a pipeline. we new the caused usually which announced please was in is me commercialization a with development By for very inflammation SarcoMed investigate to develop with end in of to let collaboration Pulmonary lymph Sarcoidosis, XXXX the promising and our to Sarcoidosis. it USA. and of inflammation, PRX-XXX Now, July, a non-binding turn pulmonary We seen
asset Development. play a our to success building Head We Yossi founder to to that appointment retired As company thank want I July, the future Hayon, scientific of role a you addition perspective research Research we’ve functions. the led we efforts new Shaaltiel valuable She with a announced At be and and her future. want as beginning operations his she valuable our -- Development. so the I team. him Yael both expand international the pipeline, is extensive highlight great Yael valuable take We Dr. in important development and brings to advance for as success. our an foundation and scientific our and and to Ph.D continue previous also the pharmaceutical long thank Vice of company’s wish will administrative tireless Yossi to be President, his big Research addition our and experience founding and and and great and will and R&D to in key who a in that team of opportunity vision the these the Protalix. will
employees Now the before last update thanks tireless the financials, I restrictions. months especially during on I this want efforts, turn over to Eyal say, all of COVID-XX and for our to to six an pandemic for our
and starting the in impacting still Israel globally. to open, While is businesses pandemic are businesses
are much and we continuing We months. to to operate in forward look have few the next
hear We even our are in I very nature Eyal, With about to the excited front please? review the to that, financials. us. progress, by but Eyal will of more call turn to excited over now
